Longitudinal changes in hippocampal texture from healthy aging to Alzheimer’s disease

Author:

Wearn Alfie1ORCID,Raket Lars Lau23ORCID,Collins D Louis14,Spreng R Nathan1456ORCID,

Affiliation:

1. Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University , Montreal, QC, Canada H3A 2B4

2. Clinical Memory Research Unit, Department of Clinical Sciences, Lund University , Lund SE-221 00 , Sweden

3. Novo Nordisk A/S , Søborg 2860 , Denmark

4. McConnell Brain Imaging Centre, McGill University , Montreal, QC, Canada H3A 2B4

5. Departments of Psychology and Psychiatry, McGill University , Montreal, QC, Canada H3A 2B4

6. Douglas Mental Health University Institute , Verdun, QC, Canada H4H 1R3

Abstract

Abstract Early detection of Alzheimer’s disease is essential to develop preventive treatment strategies. Detectible change in brain volume emerges relatively late in the pathogenic progression of disease, but microstructural changes caused by early neuropathology may cause subtle changes in the MR signal, quantifiable using texture analysis. Texture analysis quantifies spatial patterns in an image, such as smoothness, randomness and heterogeneity. We investigated whether the MRI texture of the hippocampus, an early site of Alzheimer’s disease pathology, is sensitive to changes in brain microstructure before the onset of cognitive impairment. We also explored the longitudinal trajectories of hippocampal texture across the Alzheimer’s continuum in relation to hippocampal volume and other biomarkers. Finally, we assessed the ability of texture to predict future cognitive decline, over and above hippocampal volume. Data were acquired from the Alzheimer’s Disease Neuroimaging Initiative. Texture was calculated for bilateral hippocampi on 3T T1-weighted MRI scans. Two hundred and ninety-three texture features were reduced to five principal components that described 88% of total variance within cognitively unimpaired participants. We assessed cross-sectional differences in these texture components and hippocampal volume between four diagnostic groups: cognitively unimpaired amyloid-β− (n = 406); cognitively unimpaired amyloid-β+ (n = 213); mild cognitive impairment amyloid-β+ (n = 347); and Alzheimer’s disease dementia amyloid-β+ (n = 202). To assess longitudinal texture change across the Alzheimer’s continuum, we used a multivariate mixed-effects spline model to calculate a ‘disease time’ for all timepoints based on amyloid PET and cognitive scores. This was used as a scale on which to compare the trajectories of biomarkers, including volume and texture of the hippocampus. The trajectories were modelled in a subset of the data: cognitively unimpaired amyloid-β− (n = 345); cognitively unimpaired amyloid-β+ (n = 173); mild cognitive impairment amyloid-β+ (n = 301); and Alzheimer’s disease dementia amyloid-β+ (n = 161). We identified a difference in texture component 4 at the earliest stage of Alzheimer’s disease, between cognitively unimpaired amyloid-β− and cognitively unimpaired amyloid-β+ older adults (Cohen’s d = 0.23, Padj = 0.014). Differences in additional texture components and hippocampal volume emerged later in the disease continuum alongside the onset of cognitive impairment (d = 0.30–1.22, Padj < 0.002). Longitudinal modelling of the texture trajectories revealed that, while most elements of texture developed over the course of the disease, noise reduced sensitivity for tracking individual textural change over time. Critically, however, texture provided additional information than was provided by volume alone to more accurately predict future cognitive change (d = 0.32–0.63, Padj < 0.0001). Our results support the use of texture as a measure of brain health, sensitive to Alzheimer’s disease pathology, at a time when therapeutic intervention may be most effective.

Funder

National Institutes of Health

FRQS

Alzheimer’s Disease Neuroimaging Initiative

Department of Defense

National Institute on Aging

National Institute of Biomedical Imaging and Bioengineering

AbbVie

Alzheimer’s Association

Alzheimer’s Drug Discovery Foundation

Araclon Biotech

BioClinica, Inc.

Biogen

Bristol-Myers Squibb Company

CereSpir, Inc.

Cogstate

Eisai Inc.

Elan Pharmaceuticals, Inc.

Eli Lilly and Company

EuroImmun

F. Hoffmann-La Roche Ltd.

Fujirebio

GE Healthcare

IXICO Ltd

Janssen Alzheimer Immunotherapy Research & Development, LLC.

Johnson & Johnson Pharmaceutical Research & Development LLC.

Lumosity

Lundbeck

Merck & Co., Inc.

Meso Scale Diagnostics

NeuroRx Research

Neurotrack Technologies

Novartis Pharmaceuticals Corporation

Pfizer Inc.

Piramal Imaging

Servier

Takeda Pharmaceutical Company

Transition Therapeutics

Northern California Institute for Research and Education

Alzheimer’s Therapeutic Research Institute at the University of Southern California

Laboratory for Neuro Imaging at the University of Southern California

Publisher

Oxford University Press (OUP)

Subject

Neurology,Cellular and Molecular Neuroscience,Biological Psychiatry,Psychiatry and Mental health

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3